Introduction
Increased expression levels of transforming growth factor alpha (TGF-a) and its receptor, the epidermal growth factor receptor (EGFR) are detected in squamous cell carcinoma of the head and neck (SCCHN) relative to normal mucosal epithelial cells (Grandis et al., 1996a; Grandis and Tweardy, 1993a) . In SCCHN, elevated TGF-a/EGFR expression levels are associated with increased EGFR signaling, which has been linked to proliferation, tumor progression, and decreased survival (Grandis et al., 1998c; Rubin Grandis et al., 1997) . The downstream molecules that mediate mitogenic EGFR signaling are incompletely understood.
Several potential EGFR signaling pathways have been identi®ed including ras/MAP kinase, phosphatidylinositol-3-kinase (PI-3-kinase), phospholipase Cg (PLCg), and the STAT proteins (Carpenter, 1992; Lango et al., 2001) . To date, seven STAT protein transcription factors have been identi®ed (1, 2, 3, 4, 5a, 5b, and 6) . Following tyrosine phosphorylation, STATs dimerize, translocate to the nucleus, bind to speci®c DNA response elements, and regulate transcription of target genes. Stat5 was originally described as a prolactin-inducible mammary gland factor that regulated transcription of the b-casein gene (Wakao et al., 1994) . Numerous reports have suggested an association between the activation of STAT proteins, including Stat5, and uncontrolled proliferation. Stat5 is activated in a variety of hematopoietic malignancies including erythroleukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML) Nieborowska-Skorska et al., 1999; Weber-Nordt et al., 1996) . Others have reported Stat5 activation in NIH3T3 ®broblasts as well as in the A431 vulvar squamous cell carcinoma cell line (Olayioye et al., 1999) . However, mouse knockout studies have revealed that Stat5 can play either an essential or non-essential role in oncogenesis (Schwaller et al., 2000; Sexl et al., 2000) . A clear understanding of the function of Stat5 in vivo has been complicated by the existence of two nearly identical genes, Stat5a and Stat5b, that are closely linked on murine chromosome 11 (Copeland et al., 1995) and human chromosome 17 (Lin et al., 1996) . While Stat5a and Stat5b share 93% amino acid sequence homology, only Stat5b translocated to the nucleus in response to Src and Abl kinase activation (Kazansky et al., 1999) . Stat5b, but not Stat5a, enhanced the transforming potential, cell cycle progression, and motility in NIH3T3 cells (Kazansky and Rosen, 2001) . Although these reports suggest dierent functions of Stat5a and Stat5b in cellular transformation, few studies have characterized the Stat5 isoforms in human cancers.
We previously reported activation of TGF-a/EGFR autocrine signaling in SCCHN cell lines and tissues derived from patients with head and neck cancer (Grandis et al., 1996a) . Further studies in our laboratory demonstrated that both TGF-a production and EGFR expression by SCCHN cells were linked to Stat3 activation in vitro and in vivo (Grandis et al., 1998b . Although Stat1 was also found to be constitutively activated in SCCHN cells, blockade of Stat1 was not associated with growth suppression (Grandis et al., 1998b) . Limited information is available regarding the expression and activation of Stat5 isoforms in human carcinomas. To elucidate the role of Stat5 activation in head and neck cancer, we measured expression and activation of Stat5a and Stat5b in human squamous cell carcinomas compared with normal oral epithelial cells. Further investigation using antisense oligonucleotides or dominant negative mutants of Stat5, was undertaken to determine the role of Stat5a and Stat5b in SCCHN growth control. These results indicate that constitutive activation of Stat5b, but not Stat5a, may contribute to head and neck cancer cell proliferation.
Results

Increased constitutive Stat5a and Stat5b activation is detected in SCCHN cells
Nuclear extracts from head and neck cancer cell lines were analysed by EMSA using the b-casein response element. Increased constitutive and TGF-a-stimulated Stat5 activation was detected in a series of SCCHN cell lines compared with normal epithelial cells (Figure 1a ). To con®rm that the constitutive and TGF-a-stimulated Stat5 complexes contained Stat5a and Stat5b, we performed supershift analysis, which revealed activation of both Stat5a and Stat5b in SCCHN cell lines (Figure 1b) .
Increased protein expression levels of Stat5a and Stat5b and/or increased phosphorylation of Stat5a and Stat5b proteins could explain increased activity of Stat5a and Stat5b on EMSA analysis. To determine whether the increase in constitutive Stat5 activation was associated with elevated protein expression, we performed immunoblotting studies using antisera to Stat5a or Stat5b. These experiments demonstrated an increase in Stat5a expression and Stat5a phosphorylation ( Figure 1c ) as well as increased expression of Stat5b and phosphorylated Stat5b (Figure 1d ) in SCCHN cell lines compared with normal mucosal epithelial cells. Further studies are required to determine whether elevated Stat5 levels are due to increased stability of mRNA and/or protein.
Stat5 activation is linked to TGF-a/EGFR signaling
We previously demonstrated that TGF-a is upregulated in SCCHN cell lines and tissues (Grandis et al., 1996a) . Abrogation of TGF-a in vitro and in vivo leads to SCCHN growth inhibition Grandis et al., 1998a) . To determine if TGF-a was linked to Stat5 activation, we incubated SCCHN cells with a TGF-a-neutralizing antibody. Abrogation of TGF-a resulted in decreased constitutive Stat5 activation (Figure 2a ). TGF-a binds to, and functions exclusively through stimulation of the EGFR. To determine if EGFR stimulation resulted in Stat5 activation, SCCHN cells were treated with an EGFR-speci®c tyrosine kinase inhibitor (PD153035). Using a dose of the inhibitor previously shown to block EGFR tyrosine kinase activity (20 nM), constitutive Stat5 activation was decreased at all time points examined (Figure 2b ).
Activation of Stat5b, but not Stat5a, is required for SCCHN proliferation
To elucidate the function of Stat5a versus Stat5b in SCCHN growth control, we blocked each isoform using two dierent methods. Several SCCHN cell lines were stably transfected with a dominant negative Stat5a mutant construct (Stat5aD750, carboxyl-terminal-truncated) or a dominant negative Stat5b mutant construct (Stat5bD754, carboxyl-terminal-truncated) (Moriggl et al., 1996) . EMSA analysis demonstrated that cells stably transfected with either form of mutant Stat5 demonstrated decreased constitutive Stat5 activity compared with vector-transfected control cells ( Figure 3a ). Supershift studies con®rmed the absence of Stat5a activity in DN Stat5a transfectants and the corresponding absence of Stat5b activity in DN Stat5b clones compared with vector-transfected control ( Figure 3b ). Proliferation assays showed that cells stably transfected with mutant Stat5b, were growth inhibited compared to the same cells expressing mutant Stat5a or vector-transfected control cells ( Figure 3c ).
To con®rm that speci®c abrogation of Stat5b, but not Stat5a, reduced SCCHN proliferation, phosphorothioated antisense oligonucleotides were designed to target the respective translation start sites of Stat5a or Stat5b cDNA. Incubation of SCCHN cells with Stat5a antisense oligonucleotides had no eect on growth ( Figure 4a ). In contrast, treatment of the same cells with Stat5b antisense oligonucleotides resulted in reduced proliferation (Figure 4b ). Dose-response experiments demonstrated maximum growth inhibition following treatment with 12.5 mM of antisense oligonucleotide with minimal added antiproliferative eect using higher concentrations of the Stat5b antisense nucleotides (data not shown). Immunoblotting con®rmed downregulation of Stat5a or Stat5b protein expression levels in the antisense-treated SCCHN cells ( Figure 4c ).
Discussion
This study provides evidence that SCCHN cells demonstrate increased constitutive activation of the signaling proteins, Stat5a and Stat5b, relative to Stat5 activation levels in corresponding normal epithelial cells. In transformed squamous epithelial cells, constitutive Stat5 activation appears to result, at least in part, from TGF-a/EGFR autocrine signaling. Targeting Stat5b, but not Stat5a, with dominant negative mutants or antisense oligonucleotides inhibits SCCHN growth. These results suggest that EGFR-mediated Stat5b signaling may be a critical pathway for SCCHN proliferation.
Elevated expression of TGF-a and EGFR have been detected in tumors and cell lines established from patients with SCCHN (Christensen et al., 1992; Grandis and Tweardy, 1993b) . We previously reported that TGF-a or EGFR protein levels in the primary head and neck tumor were statistically signi®cant predictors of decreased survival, independent of regional lymph node staging (Grandis et al., 1998c) . Studies targeting either ligand or receptor resulted in the inhibition of transformed but not normal mucosal epithelial cell proliferation in vitro, indicating that TGF-a and EGFR are participating in an autocrine growth pathway in SCCHN cells (Rubin Grandis et al., 1997) . Preliminary studies of cancer treatments that incorporate EGFR targeting strategies have reported encouraging results (Ciardiello et al., 2000; Shin et al., 2001) . Elucidation of the downstream EGFR mitogenic signaling components could improve treatment and The mechanisms by which growth factor-induced cell surface signals are transmitted to the nucleus and eventually precipitate cell division are only partially understood. The EGFR contains a cytoplasmic domain with intrinsic protein tyrosine kinase activity. Following ligand binding, EGFRs dimerize and become phosphorylated on multiple tyrosine residues. These phosphotyrosines enable the receptor to directly recruit signaling proteins. Several potential EGFR signaling pathways have been described, including Ras/MAP kinase, phosphotidylinositol-3-kinase, phospholipase C, and STATs (Hernandez-Sotomayor and Carpenter, 1992; Kumar et al., 1995) . STATs serve the dual function of signal transducers and activators of transcription in response to growth factors. Initially described for their role in interferon signaling, they have been shown to be activated in response to an array of cytokines and growth factors, including TGFa (Darnell, 1997; Ihle and Kerr, 1995) . TGF-a binds exclusively to and stimulates EGFR. EGFR has been shown to physically interact with STATs 1, 3, and 5 in the well-characterized A431 vulvar squamous carcinoma cell line (Olayioye et al., 1999) . We previously reported that constitutive activation of Stat3 is linked to both production of TGF-a and expression of EGFR in SCCHN cells in vitro and in vivo (Grandis et al., 1998b) . There have been few studies describing Stat5 activation in solid tumors and no reports of Stat5 activation in cutaneous or mucosal squamous cell carcinomas.
Cumulative evidence supports a role for STATs in oncogenesis in a variety of primary tumor specimens and cell lines that demonstrate elevated STAT-DNA binding activity. The results of several lines of investigation have speci®cally implicated Stat5 activation in cancer formation and tumor progression. Introduction of oncogenes, such as Bcr-Abl and HTLV-1, has led to persistent Stat5 tyrosine phosphorylation in cells (Shuai et al., 1996; de Groot et al., 1999) . Tyrosine kinase fusion genes associated with human leukemia, such as Bcr-Abl, have been linked to activation of Stat5 (Carlesso et al., 1996; Chai et al., 1997) . Stat5 has also been shown to be activated by the Tel/platelet-derived growth factor b receptor (PDGFbR), Tel/Abl, and Huntington Interacting Protein I/PDGFbR oncogenic fusion proteins (Okuda et al., 1996) . Transfection of dominant negative Stat5 mutants into murine bone marrow cultures abrogated cellular transformation by BCR/ABL (NieborowskaSkorska et al., 2000). The c-terminal truncated Stat5 dominant negative constructs used in this study have been shown to abrogate Stat5 DNA binding and block DNA binding sites in promoters of Stat5 responsive genes (Moriggl et al., 1996) . Our ®nding of decreased DNA-binding activity of Stat5 in stable transfectants is a potentially novel one and requires further investigation. Constitutive Stat5 activation obviated IL-3-dependent growth in a pro-B cell line (BaF3) (Onishi et al., 1998) . Furthermore, activation of Stat5 promoted cell cycle progression in T cells (Moriggl et al., 1996) and Stat5 activation protected cells from apoptosis through upregulation of the Stat5 target gene, Bcl-x L (Socolovsky et al., 1999) . Constitutive Stat5 activation has been detected primarily in hematopoietic malignancies such as acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML) (Migone et al., 1995) . Activation of Stat5 target genes by Tel/JAK2 can stimulate cell proliferation. However, in the presence of Bcr/Abl fusion proteins, Stat5 does not appear to regulate cell growth, although its activation is a hallmark of these leukemias (Lacronique et al., 2000) . It has been suggested that activation of Stat5 is both necessary and sucient for malignant transformation .
Several reports suggest dierential functions of Stat5a and Stat5b. Studies of Stat5a and Stat5b knockout mice have revealed signi®cantly dierent phenotypes. Stat5a-de®cient animals showed impaired mammary gland development, lactation and a partial defect in T-cell growth (Liu et al., 1997) . In contrast, Stat5b knockout mice were characterized by defects related to growth hormone actions as well as alterations in T-cell growth and in natural killer cell development (Udy et al., 1997) . The regulation and function of Stat5a and Stat5b may be highly dependent on the speci®c cell type and activating stimulus. Expression of a dominant negative mutant form of Stat5a markedly interfered with growth factor inde- pendence mediated by TEL-JAK2 in murine Ba/F3 cells (Lacronique et al., 2000) . Examining the tyrosine phosphorylation status of Stat5a and Stat5b revealed selective Stat5b phosphorylation, in the absence of Stat5a phosphorylation, in 15% of human AML samples (Hayakawa et al., 1998) . Puri®ed Stat5a protein had a higher DNA binding anity than Stat5b, binding to DNA as both a dimer and as a tetramer complex, compared with Stat5b which bound only as dimers (Soldaini et al., 2000) .
However, it appears that some cancers that are characterized by constitutively phosphorylated Stat5 are not altered by Stat5 abrogation. In these cases, the role of Stat5 may be redundant with other critical transforming events that are sucient to cause the disease. In addition, failure to distinguish the role of Stat5a from Stat5b may obscure key dierences. The results of the present study suggest that Stat5b may be an important mitogenic signaling molecule in SCCHN where TGF-a activate Stat5b via EGFR autocrine signaling. This is the ®rst report demonstrating that abrogating Stat5a versus Stat5b has a dierential impact on the proliferation of human cancer cells. Stat5b appears to mediate growth pathways in SCCHN, and may therefore serve as a therapeutic target in the treatment of this disease.
Materials and methods
Cells
Cell lines derived from SCCHN patients were grown in DMEM (Cellgro, Washington, DC, USA). With 15% FBS (GIBCO Laboratories, Grand Island, NY, USA), plus 100 U/ml of penicillin and 100 U/ml of streptomycin (GIBCO) (Heo et al., 1989) . Several SCCHN cell lines are part of a large collection established in the Department of Otolaryngology at the University of Pittsburgh (PCI-15b, PCI-37a) in addition to UM-22B (Virolainen et al., 1983) and 1483 (Sacks et al., 1988) . Normal mucosal epithelial cells were obtained from primary cultures established from oropharyngeal mucosa harvested from patients undergoing non-oncologic head and neck procedures as described by us previously (Grandis et al., 1996b) .
Reagents
Rh-TGF-a was obtained from Calbiochem/Oncogene Science (Cambridge, MA, USA). Complementary duplex oligonucleotides were synthesized based on the published sequences of STAT DNA-binding elements with the addition of GGGG at the 5' termini to allow radiolabeling as described previously (b-casein promoter: 5'-AGATTTCTAGGAATTCAAATC-3') (Sattler et al., 1995) . The TGF-a-neutralizing antibody was obtained from Oncogene Science (Cambridge, MA, USA; Ab#3). The EGFR-speci®c tyrosine kinase inhibitor, PD 153035, was obtained from Calbiochem/Oncogene Science (Fry et al., 1994) and used as described previously (Grandis et al., 1998b) .
Transfection of SCCHN cells with dominant negative Stat5a Stat5b constructs
Plasmids expressing mutant Stat5aD750 or Stat5bD754 (carboxyl-terminal-truncated) were kindly provided by Dr Bernd H Groner (Moriggl et al., 1996) and stably co- transfected with a neomycin resistance marker (5a/neo ratio 50 : 1, 5b/neo 50 : 1) into several SCCHN cell lines using G418 selection conditions (400 mg/ml). Several clones (3 ± 5) were isolated from each cell line using a cloning ring and expanded, and electrophoretic mobility shift assays (EMSA) were performed to determine that the incorporated mutant Stat5 protein functioned in a dominant negative fashion as previously described (Moriggl et al., 1996) . The growth rates of individual clones were determined by erythrosin B dye exclusion at serial time points.
Antisense oligodeoxynucleotide studies
Phosphorothioated 21-mer oligodeoxynucleotides were synthesized on an Applied Biosystem 394 synthesizer by means of b-cyanothylphysphoramidite chemistry to minimize degradation of the oligonucleotides by endogenous nucleases. We have previously determined the optimum conditions for oligonucleotide uptake by SCCHN cells via end labeling followed by measuring counts in nuclear and cytoplasmic fractions of cell lysates (*40% uptake in nucleus by 24 h) (Grandis et al., 1998a) . The antisense oligonucleotides were directed against the translation start site (AUG codon) and surrounding nucleotides of the human Stat5a or Stat5b genes. The Stat 5a antisense oligonucleotide sequences was 5'-TGA ACG GCC ATG GCG GGC TGG-3' and the corresponding sense oligonucleotide sequence was 5'-CCA GCC CGC CAT GGC GCT TCA-3'. The Stat 5b antisense oligonucleotide sequence was 5'-CCA CAC AGC CAT GTT TAC CCG-3' and the corresponding sense oligonucleotide sequence was 5'-CGG GTA AAC ATG GCT GTG TGG-3'. To examine the eect of antisense oligonucleotide treatment on SCCHN cell growth, cells were plated at a density of 10 4 cells/microtiter well in 24-well polystyrene plates (Falcon Plastics, Cockeysville, MD, USA). After 24 h, at which point the cells had reached 30 ± 40% con¯uence, 250 ml of fresh culture medium containing 12.5 mM antisense oligonucleotide targeted against the translation start site of human Stat5a or Stat5b was added. As controls, cells received an equal concentration of the corresponding sense oligonucleotides or the same medium without oligonucleotides. Cell counts were performed over a period of 6 days, with two replicate samples for each time point.
Electrophoretic mobility shift assay (EMSA)
Adherent cells (510 6 ) were grown in 10-cm plastic tissue culture dishes, rested for 6 h in SFM, and then incubated for 30 min in SFM with or without TGF-a (10 ng/ml for 30 min), washed, and harvested by scraping with a rubber policeman. Nuclear extracts were prepared and EMSAs were performed on 4% native polyacrylamide gels as described (Sadowski et al., 1993; Wong et al., 1994) . Brie¯y, the cells were centrifuged at 200 g for 5 min, washed with PBS, and resuspended in 1 ml ice-cold buer containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, 1 mM NaF, 0.5 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl¯uoride, 1 mg/ml pepstatin, 5 mg/ml aptotinin, and 2 mg/ml leupeptin. After 30-min incubation on ice, the cells were centrifuged at 10 000 g for 1 min. The pelleted nuclei were resuspended in 100 ml buer containing 20 mM HEPES (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM Na 3 VO 4 , 10 mM NaF, 0.5 mM DTT, 0.2 mM phenylmethylsulfonyl¯uoride, 1 mg/ml pepstatin, 5 mg/ml aptotinin, and 2 mg/ml leupeptin. Nuclear proteins were liberated during a 30-min incubation on ice. The supernatant was clari®ed by a 10-min centrifuge (10 000 g, and the extract was aliquoted and stored at 7808C until used. Protein concentration were determined using a protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Probes were prepared by labeling double-stranded oligonucleotides with [g-32 P]ATP and T4 polynucleotide kinase. Binding was performed in a 20-ml volume with 200 pg radiolabeled probe, 10 mg protein, 5 mm Tris (pH 7.9), 15 mm HEPES (pH 7.9), 80 mm KCl, 3.5 mm MgCl 2 , 5 mm EDTA, 0.1% Tween 20, 5 mm DTT, 10% glycerol, and 100 mg/ml poly(dIdC). After incubation at room temperature for 20 min, the products were electrophoresed on 4% polyacrylamide gels containing 2.5% glycerol and 0.56TBE (22 mM Tris, 22 mM boric acid, and 0.5 mM EDTA). A 50-fold excess of unlabeled double stranded oligonucleotides was used as cold competitor. For supershift studies, the nuclear proteins were incubated for 30 min at room temperature with polyclonal antisera (200 ng) raised against Stat5a and Stat5b (Upstate Biotechnology, Inc., Lake Placid, NY, USA) before addition of the probe.
Immunoblotting and immunoprecipitation
Cells were grown to near con¯uence in 100-mm cultured dishes. Thereafter, cells were washed three times with ice-cold PBS and harvested in 1 ml lysis buer (10 mM Tris-HCl, pH 7.6, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 1 mM Na 3 VO 4 , 1% Triton X-100, 1 mM phenylmethylsulfonyl¯uoride, 5 mg/ml aprotinin, 1 mg/ml pepstatin A, and 2 mg/ml leupeptin). Aliquots from cleared lysates containing 50 mg protein were subjected to electrophoresis on SDS ± PAGE. Separated proteins were electroblotted to a nitrocellulose membrane (MSI; Westboro, MA, USA). Detection of Stat5a or Stat5b was performed by Western blotting with anti-Stat5a or Stat5b antibody directed against human Stat5a or Stat5b (Upstate Biotechnology, Inc.) respectively. Stat5a or Stat5b phosphorylation was determined by immunoprecipitation with antiphosphotyrosine monoclonal antibody (PY20, Transduction Laboratories, Inc.), followed by immunoblotting with anti-Stat5a or Stat5b (Upstate Biotechnology, Inc.) antisera.
